Mitchell S. von Itzstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitchell S. von Itzstein has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- David E. Gerber
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX
37 shared publications - Jonathan E. Dowell
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
21 shared publications - Ang Gao
O’Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA
20 shared publications - Arjun Gupta
City of Hope Cancer Center, Phoenix, AZ
20 shared publications - David Ross Camidge
University of Colorado Cancer Center, Aurora, CO 80045, USA
20 shared publications - Farjana Fattah
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
20 shared publications
Latest Publications
- 18 June 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (9) , 926-947
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy
Background: Immune checkpoint inhibitors (ICIs) have transformed oncology practice. However, treatment response remains heterogeneous, rendering predictive biomarkers critical for optimal patient care. The 3 established biomarkers, programmed death-ligand 1, tumor mutational burden (TMB), and microsatellite instability-high/deficient mismatch repair, are approved and clinically validated but are modest predictors of benefit. As a result, multiple novel predictive biomarkers remain under investigation. Content: This review highlights established and investigational predictive ICI efficacy biomarkers. For established biomarkers, we describe biology, assay modalities, approved companion diagnostics, landmark studies, and notable limitations. Due to the multisystem nature of antitumor immune effects, investigational biomarkers span multiple domains, including tumor genomic biomarkers (e.g., mutational signatures, TMB, neoantigen clonality), tumor microenvironment (e.g., tumor-infiltrating lymphocytes [TILs], tertiary lymphoid structures), systemic immune biomarkers (e.g., cytokines, autoantibodies, glycoproteins, peripheral blood mononuclear cells), and the microbiome (e.g., gastrointestinal microbial diversity, responder-enriched taxa). Summary: The established biomarkers PD-L1, TMB, and microsatellite instability-high/deficient mismatch repair inform ICI use in clinical practice but have important limitations. Multiple investigational biomarkers show promise in refining patient selection and optimizing therapy. Moving forward, increased assay harmonization, prospective validation, and standardized parameters may improve performance. Composite models integrating complementary signals across domains may further individualize treatment and lead to an era of personalized cancer immunotherapy.
- 18 June 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (9) , 926-947
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy
Background: Immune checkpoint inhibitors (ICIs) have transformed oncology practice. However, treatment response remains heterogeneous, rendering predictive biomarkers critical for optimal patient care. The 3 established biomarkers, programmed death-ligand 1, tumor mutational burden (TMB), and microsatellite instability-high/deficient mismatch repair, are approved and clinically validated but are modest predictors of benefit. As a result, multiple novel predictive biomarkers remain under investigation. Content: This review highlights established and investigational predictive ICI efficacy biomarkers. For established biomarkers, we describe biology, assay modalities, approved companion diagnostics, landmark studies, and notable limitations. Due to the multisystem nature of antitumor immune effects, investigational biomarkers span multiple domains, including tumor genomic biomarkers (e.g., mutational signatures, TMB, neoantigen clonality), tumor microenvironment (e.g., tumor-infiltrating lymphocytes [TILs], tertiary lymphoid structures), systemic immune biomarkers (e.g., cytokines, autoantibodies, glycoproteins, peripheral blood mononuclear cells), and the microbiome (e.g., gastrointestinal microbial diversity, responder-enriched taxa). Summary: The established biomarkers PD-L1, TMB, and microsatellite instability-high/deficient mismatch repair inform ICI use in clinical practice but have important limitations. Multiple investigational biomarkers show promise in refining patient selection and optimizing therapy. Moving forward, increased assay harmonization, prospective validation, and standardized parameters may improve performance. Composite models integrating complementary signals across domains may further individualize treatment and lead to an era of personalized cancer immunotherapy.
- Open Access
- 13 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Deciphering small sequence differences in T cell receptor-antigen pairing
T cells have important functions in development and disease processes through T cell receptor (TCR)-dependent activities. Many tools were developed to predict the binding between TCRs and antigens. However, one of the uncertainties is whether such tools can decipher how small changes in the TCRs or antigenic peptides contribute to binding. We develop a deep learning model, pMTnet-omni, which not only predicts the binding vs. non-binding of TCRs towards pMHCs, but also distinguishes the stronger vs. weaker binding of TCRs similar in sequence. We leverage this capability to interpret the biological rules that govern TCR-antigen pairing. This also enables pMTnet-omni to accurately predict variant TCRs with desired stronger or weaker binding to the antigen, in conjunction with a Lab-in-the-Loop (LiL) mechanism. We show that pMTnet-omni can also predict binding of TCRs towards similar pMHCs. Overall, we provide a flexible toolkit for research and translational applications involving antigens and TCRs.
- 13 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDeciphering small sequence differences in T cell receptor-antigen pairing
T cells have important functions in development and disease processes through T cell receptor (TCR)-dependent activities. Many tools were developed to predict the binding between TCRs and antigens. However, one of the uncertainties is whether such tools can decipher how small changes in the TCRs or antigenic peptides contribute to binding. We develop a deep learning model, pMTnet-omni, which not only predicts the binding vs. non-binding of TCRs towards pMHCs, but also distinguishes the stronger vs. weaker binding of TCRs similar in sequence. We leverage this capability to interpret the biological rules that govern TCR-antigen pairing. This also enables pMTnet-omni to accurately predict variant TCRs with desired stronger or weaker binding to the antigen, in conjunction with a Lab-in-the-Loop (LiL) mechanism. We show that pMTnet-omni can also predict binding of TCRs towards similar pMHCs. Overall, we provide a flexible toolkit for research and translational applications involving antigens and TCRs.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (2) , 44
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition
- 1 February 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (2) , 44
Open AccessA new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition
- Open Access
- 27 January 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (2) , 39
Metabolic syndrome and immune-related adverse events
Background Years into the immune checkpoint inhibitor (ICI) era, immune-related adverse events (irAE) remain largely unpredictable. Prior studies have examined irAE associations with weight and metabolic diseases, yielding mixed findings. We therefore analyzed these and other variables potentially associated with heightened inflammation and irAE development. Methods For ICI-treated individuals enrolled in a prospective institutional clinical and biospecimen registry, we collected demographic, clinical, laboratory, and residence data, pre-ICI serum cytokine levels, and irAE details. We calculated metabolic syndrome (MetS) and area deprivation index (ADI, a measure of neighborhood socioeconomic status), both of which have been associated with heightened inflammation. Patients were categorized as having MetS if they had ≥ 3 of 5 criteria at ICI initiation: hypertension, obesity, elevated HbA1c, low HDL, elevated triglycerides. Baseline serum cytokine/chemokine levels were determined using a multiplex platform. We analyzed associations across variables using logistic regression, Mann–Whitney U, and Cochran Armitage tests, accounting for multiple comparisons. Results Overall, 178 ICI-treated patients were included in the analysis, of whom 99 (56%) were classified as having MetS. In multivariable analysis, patients with MetS had greater odds of both grade ≥ 2 irAE (OR 2.82; 95% CI, 1.35–6.14; P = 0.007) and grade ≥ 3 irAE (OR 3.53; 95% CI 1.27–11.68; P = 0.02). However, MetS was not associated with pre-treatment cytokine levels. In contrast, ADI was associated with multiple inflammatory cytokines but not with MetS or irAE. Conclusions MetS is associated with increased likelihood of moderate and severe irAE. The mechanism and mitigation of this risk merit further investigation.
- 27 January 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (2) , 39
Open AccessMetabolic syndrome and immune-related adverse events
Background Years into the immune checkpoint inhibitor (ICI) era, immune-related adverse events (irAE) remain largely unpredictable. Prior studies have examined irAE associations with weight and metabolic diseases, yielding mixed findings. We therefore analyzed these and other variables potentially associated with heightened inflammation and irAE development. Methods For ICI-treated individuals enrolled in a prospective institutional clinical and biospecimen registry, we collected demographic, clinical, laboratory, and residence data, pre-ICI serum cytokine levels, and irAE details. We calculated metabolic syndrome (MetS) and area deprivation index (ADI, a measure of neighborhood socioeconomic status), both of which have been associated with heightened inflammation. Patients were categorized as having MetS if they had ≥ 3 of 5 criteria at ICI initiation: hypertension, obesity, elevated HbA1c, low HDL, elevated triglycerides. Baseline serum cytokine/chemokine levels were determined using a multiplex platform. We analyzed associations across variables using logistic regression, Mann–Whitney U, and Cochran Armitage tests, accounting for multiple comparisons. Results Overall, 178 ICI-treated patients were included in the analysis, of whom 99 (56%) were classified as having MetS. In multivariable analysis, patients with MetS had greater odds of both grade ≥ 2 irAE (OR 2.82; 95% CI, 1.35–6.14; P = 0.007) and grade ≥ 3 irAE (OR 3.53; 95% CI 1.27–11.68; P = 0.02). However, MetS was not associated with pre-treatment cytokine levels. In contrast, ADI was associated with multiple inflammatory cytokines but not with MetS or irAE. Conclusions MetS is associated with increased likelihood of moderate and severe irAE. The mechanism and mitigation of this risk merit further investigation.
- Open Access
- 5 January 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100952
Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings
- 5 January 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100952
Open AccessImmune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings
- 26 September 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (10) , 2729-2738
Nipah and Hendra Viruses Use an Adjustable Latch in Receptor Engagement
Nipah (NiV) and Hendra viruses (HeV) have emerged as deadly zoonotic pathogens over the last three decades. Like all paramyxoviruses, Henipaviruses utilize a surface glycoprotein to attach to and invade targeted cells. Inhibiting this attachment glycoprotein is a promising strategy for developing effective antihenipaviral drugs. A multidisciplinary approach has been employed to investigate the structures of HeV and NiV attachment glycoproteins, identifying a flexible region near their binding site. This region, loop 240, can adopt an open conformation in unliganded attachment glycoproteins and a closed "latch" conformation in the presence of their cognate receptor Ephrin B2. Site-directed mutagenesis of the HeV attachment glycoproteins has shown that the engagement of R242 with Ephrin B2 plays an important role in the binding mechanism. This discovery provides greater insight into the dynamic nature of henipaviral attachment proteins and has implications for antiviral drug development.
- 26 September 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (10) , 2729-2738
Nipah and Hendra Viruses Use an Adjustable Latch in Receptor Engagement
Nipah (NiV) and Hendra viruses (HeV) have emerged as deadly zoonotic pathogens over the last three decades. Like all paramyxoviruses, Henipaviruses utilize a surface glycoprotein to attach to and invade targeted cells. Inhibiting this attachment glycoprotein is a promising strategy for developing effective antihenipaviral drugs. A multidisciplinary approach has been employed to investigate the structures of HeV and NiV attachment glycoproteins, identifying a flexible region near their binding site. This region, loop 240, can adopt an open conformation in unliganded attachment glycoproteins and a closed "latch" conformation in the presence of their cognate receptor Ephrin B2. Site-directed mutagenesis of the HeV attachment glycoproteins has shown that the engagement of R242 with Ephrin B2 plays an important role in the binding mechanism. This discovery provides greater insight into the dynamic nature of henipaviral attachment proteins and has implications for antiviral drug development.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 4. Cytokine changes (post-selinexor, pre-docetaxel) significantly associated with clinical outcomes.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 4. Cytokine changes (post-selinexor, pre-docetaxel) significantly associated with clinical outcomes.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 1. Next generation sequencing results (n=16 cases).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 1. Next generation sequencing results (n=16 cases).
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 3. Baseline cytokines significantly associated with clinical outcomes.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 3. Baseline cytokines significantly associated with clinical outcomes.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.